OATD-02
Oncology (Solid Tumors)
Key Facts
About Molecure
Molecure is a clinical-stage biotech with a mission to develop novel small molecule drugs for high-unmet-need diseases in oncology and inflammation. Its key achievement is building two proprietary discovery platforms targeting RNA and protein-protein interactions (PPIs), translating into a maturing internal pipeline. The company's strategy involves advancing its lead programs through clinical proof-of-concept while leveraging its platforms for new discovery and potential partnerships. Its 2021 IPO on the Warsaw Stock Exchange provided capital to execute this strategy and establish Poland as a hub for innovative drug discovery.
View full company profileTherapeutic Areas
Other Oncology (Solid Tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| ANXV | Annexin Pharmaceuticals | Preclinical |
| Athebody® DARPins for Targeted Radioligands (with POINT Biopharma) | Athebio | Pre-clinical |
| AB821 | Asher Biotherapeutics | Preclinical |
| VEGF Kinoid | Neovacs | Preclinical |
| Undisclosed Preclinical Pipeline | OncoResponse | Preclinical |
| Undisclosed Platform Program | Da Zen Theranostics | Pre-clinical |
| Compound42 | Abbmira Therapeutics | Pre-clinical |
| Clinical Decision Support Service | Curematch | Commercial |
| CV6-168 | CV6 Therapeutics | Phase 1a |
| Chemophototherapy (CPT) | POP Biotechnologies | Pre-clinical |
| HRD Testing Solution | SeqOne Genomics | Commercial |
| Platform Validation & Partnership Development | SingleCell Biotechnology | Pre-clinical |